H.C. Wainwright lowered the firm’s price target on AC Immune (ACIU) to $12 from $16 and keeps a Buy rating on the shares. The interim 26-week data from the ACI-7104.056 VacSYn Phase 2 trial showed that the vaccine continues to be safe, the analyst tells investors in a research note. The firm updated the stock’s discount rate to better reflect the current macro environment for Smid-cap biotech companies.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACIU:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue